Kodiak Sciences (KOD) Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
KOD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kodiak Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.25 |
| 52 Week High | US$21.17 |
| 52 Week Low | US$1.92 |
| Beta | 2.71 |
| 1 Month Change | 74.57% |
| 3 Month Change | 101.69% |
| 1 Year Change | 268.18% |
| 3 Year Change | 163.67% |
| 5 Year Change | -84.06% |
| Change since IPO | 99.31% |
Recent News & Updates
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Oct 03
Kodiak Sciences: Odds May Be Narrowing For Longer Lasting Eye Disease Med Approval
Aug 22Recent updates
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Oct 03Kodiak Sciences: Odds May Be Narrowing For Longer Lasting Eye Disease Med Approval
Aug 22Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Feb 24We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Dec 13Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Nov 15We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Aug 02We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Shareholder Returns
| KOD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.6% | 4.3% | 0.4% |
| 1Y | 268.2% | 8.4% | 14.0% |
Return vs Industry: KOD exceeded the US Biotechs industry which returned 7.7% over the past year.
Return vs Market: KOD exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| KOD volatility | |
|---|---|
| KOD Average Weekly Movement | 23.6% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: KOD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KOD's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 121 | Victor Perlroth | kodiak.com |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.
Kodiak Sciences Inc. Fundamentals Summary
| KOD fundamental statistics | |
|---|---|
| Market cap | US$1.03b |
| Earnings (TTM) | -US$199.82m |
| Revenue (TTM) | n/a |
Is KOD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$199.83m |
| Earnings | -US$199.82m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KOD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/12 06:28 |
| End of Day Share Price | 2025/11/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kodiak Sciences Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Anita Dushyanth | Berenberg |
| Matthew Luchini | BMO Capital Markets Equity Research |